Yahoo
Stockholm - Free Realtime Quote SEK

Biovica International AB (publ) (BIOVIC-B.ST)

0.5040 -0.0260 (-4.91%)
As of 9:53:30 AM GMT+2. Market Open.
Chart Range Bar
Loading chart for BIOVIC-B.ST
  • Previous Close 0.5300
  • Open 0.5280
  • Bid 0.5020 x --
  • Ask 0.5040 x --
  • Day's Range 0.5040 - 0.5280
  • 52 Week Range 0.2700 - 0.6840
  • Volume 27,752
  • Avg. Volume 753,895
  • Market Cap (intraday) 147.123M
  • Beta (5Y Monthly) 1.15
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.60

Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

www.biovica.com

25

Full Time Employees

April 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/14/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

BIOVIC-B.ST
36.22%
OMX Stockholm 30 Index (^OMX)
13.45%

1-Year Return

BIOVIC-B.ST
25.66%
OMX Stockholm 30 Index (^OMX)
24.23%

3-Year Return

BIOVIC-B.ST
94.07%
OMX Stockholm 30 Index (^OMX)
48.45%

5-Year Return

BIOVIC-B.ST
99.02%
OMX Stockholm 30 Index (^OMX)
35.89%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 3.29M
Earnings -17.85M

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-20M
-15M
-10M
-5M
0

Analyst Insights

View More

Analyst Price Targets

0.60
0.60 Average
0.5040 Current
0.60 High

Statistics

View More

Valuation Measures

Annual
As of 8/11/2026
  • Market Cap

    153.55M

  • Enterprise Value

    87.43M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.65

  • Price/Book (mrq)

    1.86

  • Enterprise Value/Revenue

    7.06

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.13%

  • Return on Equity (ttm)

    -107.86%

  • Revenue (ttm)

    13.48M

  • Net Income Avi to Common (ttm)

    -69.86M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    70.41M

  • Total Debt/Equity (mrq)

    4.98%

  • Levered Free Cash Flow (ttm)

    -39.22M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: